Global Buprenorphine Market
Global Buprenorphine Market

Buprenorphine Comprehensive Study by Application (Hospital, Clinic, Other), Side Effect (Sedation, Dizziness, Headache, Low blood pressure (hypotension), Slow breathing), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Dosages (Injectable Solution, Tablet) Players and Region - Global Market Outlook to 2026

Buprenorphine Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Dec 2021 Edition 248 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Buprenorphine?
Buprenorphine is a type of opioid which is used to treating opioid addiction, acute pain, and chronic pain. It can be injected (intravenous and subcutaneous), used for a skin patch (transdermal), or implanted under the tongue (sublingual), in the cheek (buccal), by injection (intravenous and subcutaneous), as a skin patch (transdermal), or as an implant. It is probably started when withdrawal symptoms start that for the first two days of treatment under direct supervision of a health-care practitioner for opioid use disorder. To deter injectable usage, the combined formulation of buprenorphine/naloxone (Suboxone) is advised. In most cases, optimum pain relief occurs within an hour, with effects lasting up to 24 hours. Treatment with buprenorphine has the potential to cause psychological or physiological (physical) dependence. It also has a lengthy half-life of 24 to 60 hours, a gradual onset of effect, and a long duration of action.

The market study is broken down, by Application (Hospital, Clinic and Other) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies Analysts at AMA Research estimates that Players from Indian will contribute to the maximum growth of Global Buprenorphine market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Siegfried Pharma AG (Switzerland), Sanofi (France), Johnson Matthey (United Kingdom), Mallinckrodt (United Kingdom), Noramco (United States), Unichem Laboratories (India), Arevipharma GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Rusan Pharma (India) and Micro Orgo Chem (India) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Buprenorphine market by Type, Application and Region.

On the basis of geography, the market of Buprenorphine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Side Effect , the sub-segment i.e. Sedation will boost the Buprenorphine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Buprenorphine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosages, the sub-segment i.e. Injectable Solution will boost the Buprenorphine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.




Market Trend
  • Increasing Investment In RD To Developing Cost Effective Drugs

Market Drivers
  • Rising The Prevalence Of Chronic Pain

Opportunities
  • Government Favorable Initiatives For Com-batting Problem Of Substance Dependency And Drug

Restraints
  • Lack Of Licensed Doctor For Prescribing Buprenorphine

Challenges
  • Slow Act Impact Of Buprenorphine
  • Rising Awareness About The Side Effects Of Buprenorphine


Key Target Audience
Buprenorphine Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Siegfried Pharma AG (Switzerland), Sanofi (France), Johnson Matthey (United Kingdom), Mallinckrodt (United Kingdom), Noramco (United States), Unichem Laboratories (India), Arevipharma GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Rusan Pharma (India) and Micro Orgo Chem (India) etc.

2. Can we have customized study for Buprenorphine Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Buprenorphine Market by 2026?
Analysts at AMA estimates Buprenorphine Market to reach USD Million by 2026.
Report Objectives / Segmentation Covered
By Application
  • Hospital
  • Clinic
  • Other
By Side Effect
  • Sedation
  • Dizziness
  • Headache
  • Low blood pressure (hypotension)
  • Slow breathing

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Dosages
  • Injectable Solution
  • Tablet

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising The Prevalence Of Chronic Pain
    • 3.3. Market Challenges
      • 3.3.1. Slow Act Impact Of Buprenorphine
      • 3.3.2. Rising Awareness About The Side Effects Of Buprenorphine
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment In RD To Developing Cost Effective Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Buprenorphine, by Application, Side Effect , Distribution Channel, Dosages and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Buprenorphine (Value)
      • 5.2.1. Global Buprenorphine by: Application (Value)
        • 5.2.1.1. Hospital
        • 5.2.1.2. Clinic
        • 5.2.1.3. Other
      • 5.2.2. Global Buprenorphine by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Buprenorphine by: Dosages (Value)
        • 5.2.3.1. Injectable Solution
        • 5.2.3.2. Tablet
      • 5.2.4. Global Buprenorphine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Buprenorphine (Price)
  • 6. Buprenorphine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Siegfried Pharma AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson Matthey (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mallinckrodt (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Noramco (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Unichem Laboratories (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Arevipharma GmbH (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Rusan Pharma (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Micro Orgo Chem (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Buprenorphine Sale, by Application, Side Effect , Distribution Channel, Dosages and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Buprenorphine (Value)
      • 7.2.1. Global Buprenorphine by: Application (Value)
        • 7.2.1.1. Hospital
        • 7.2.1.2. Clinic
        • 7.2.1.3. Other
      • 7.2.2. Global Buprenorphine by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Buprenorphine by: Dosages (Value)
        • 7.2.3.1. Injectable Solution
        • 7.2.3.2. Tablet
      • 7.2.4. Global Buprenorphine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Buprenorphine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Buprenorphine: by Application(USD Million)
  • Table 2. Buprenorphine Hospital , by Region USD Million (2015-2020)
  • Table 3. Buprenorphine Clinic , by Region USD Million (2015-2020)
  • Table 4. Buprenorphine Other , by Region USD Million (2015-2020)
  • Table 5. Buprenorphine: by Distribution Channel(USD Million)
  • Table 6. Buprenorphine Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 7. Buprenorphine Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Buprenorphine Online Pharmacies , by Region USD Million (2015-2020)
  • Table 9. Buprenorphine: by Dosages(USD Million)
  • Table 10. Buprenorphine Injectable Solution , by Region USD Million (2015-2020)
  • Table 11. Buprenorphine Tablet , by Region USD Million (2015-2020)
  • Table 12. South America Buprenorphine, by Country USD Million (2015-2020)
  • Table 13. South America Buprenorphine, by Application USD Million (2015-2020)
  • Table 14. South America Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 15. South America Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 16. South America Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 17. Brazil Buprenorphine, by Application USD Million (2015-2020)
  • Table 18. Brazil Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 19. Brazil Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 20. Brazil Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 21. Argentina Buprenorphine, by Application USD Million (2015-2020)
  • Table 22. Argentina Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 23. Argentina Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 24. Argentina Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 25. Rest of South America Buprenorphine, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 27. Rest of South America Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 28. Rest of South America Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 29. Asia Pacific Buprenorphine, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Buprenorphine, by Application USD Million (2015-2020)
  • Table 31. Asia Pacific Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 32. Asia Pacific Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 33. Asia Pacific Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 34. China Buprenorphine, by Application USD Million (2015-2020)
  • Table 35. China Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 36. China Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 37. China Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 38. Japan Buprenorphine, by Application USD Million (2015-2020)
  • Table 39. Japan Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 40. Japan Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 41. Japan Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 42. India Buprenorphine, by Application USD Million (2015-2020)
  • Table 43. India Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 44. India Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 45. India Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 46. South Korea Buprenorphine, by Application USD Million (2015-2020)
  • Table 47. South Korea Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 48. South Korea Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 49. South Korea Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 50. Australia Buprenorphine, by Application USD Million (2015-2020)
  • Table 51. Australia Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 52. Australia Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 53. Australia Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Buprenorphine, by Application USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 58. Europe Buprenorphine, by Country USD Million (2015-2020)
  • Table 59. Europe Buprenorphine, by Application USD Million (2015-2020)
  • Table 60. Europe Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 61. Europe Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 62. Europe Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 63. Germany Buprenorphine, by Application USD Million (2015-2020)
  • Table 64. Germany Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 65. Germany Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 66. Germany Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 67. France Buprenorphine, by Application USD Million (2015-2020)
  • Table 68. France Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 69. France Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 70. France Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 71. Italy Buprenorphine, by Application USD Million (2015-2020)
  • Table 72. Italy Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 73. Italy Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 74. Italy Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 75. United Kingdom Buprenorphine, by Application USD Million (2015-2020)
  • Table 76. United Kingdom Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 77. United Kingdom Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 78. United Kingdom Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 79. Netherlands Buprenorphine, by Application USD Million (2015-2020)
  • Table 80. Netherlands Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 81. Netherlands Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 82. Netherlands Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 83. Rest of Europe Buprenorphine, by Application USD Million (2015-2020)
  • Table 84. Rest of Europe Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 85. Rest of Europe Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 86. Rest of Europe Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 87. MEA Buprenorphine, by Country USD Million (2015-2020)
  • Table 88. MEA Buprenorphine, by Application USD Million (2015-2020)
  • Table 89. MEA Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 90. MEA Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 91. MEA Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 92. Middle East Buprenorphine, by Application USD Million (2015-2020)
  • Table 93. Middle East Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 94. Middle East Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 95. Middle East Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 96. Africa Buprenorphine, by Application USD Million (2015-2020)
  • Table 97. Africa Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 98. Africa Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 99. Africa Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 100. North America Buprenorphine, by Country USD Million (2015-2020)
  • Table 101. North America Buprenorphine, by Application USD Million (2015-2020)
  • Table 102. North America Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 103. North America Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 104. North America Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 105. United States Buprenorphine, by Application USD Million (2015-2020)
  • Table 106. United States Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 107. United States Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 108. United States Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 109. Canada Buprenorphine, by Application USD Million (2015-2020)
  • Table 110. Canada Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 111. Canada Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 112. Canada Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 113. Mexico Buprenorphine, by Application USD Million (2015-2020)
  • Table 114. Mexico Buprenorphine, by Side Effect USD Million (2015-2020)
  • Table 115. Mexico Buprenorphine, by Distribution Channel USD Million (2015-2020)
  • Table 116. Mexico Buprenorphine, by Dosages USD Million (2015-2020)
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Buprenorphine: by Application(USD Million)
  • Table 128. Buprenorphine Hospital , by Region USD Million (2021-2026)
  • Table 129. Buprenorphine Clinic , by Region USD Million (2021-2026)
  • Table 130. Buprenorphine Other , by Region USD Million (2021-2026)
  • Table 131. Buprenorphine: by Distribution Channel(USD Million)
  • Table 132. Buprenorphine Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 133. Buprenorphine Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 134. Buprenorphine Online Pharmacies , by Region USD Million (2021-2026)
  • Table 135. Buprenorphine: by Dosages(USD Million)
  • Table 136. Buprenorphine Injectable Solution , by Region USD Million (2021-2026)
  • Table 137. Buprenorphine Tablet , by Region USD Million (2021-2026)
  • Table 138. South America Buprenorphine, by Country USD Million (2021-2026)
  • Table 139. South America Buprenorphine, by Application USD Million (2021-2026)
  • Table 140. South America Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 141. South America Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 142. South America Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 143. Brazil Buprenorphine, by Application USD Million (2021-2026)
  • Table 144. Brazil Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 145. Brazil Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 146. Brazil Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 147. Argentina Buprenorphine, by Application USD Million (2021-2026)
  • Table 148. Argentina Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 149. Argentina Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 150. Argentina Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 151. Rest of South America Buprenorphine, by Application USD Million (2021-2026)
  • Table 152. Rest of South America Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 153. Rest of South America Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 154. Rest of South America Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 155. Asia Pacific Buprenorphine, by Country USD Million (2021-2026)
  • Table 156. Asia Pacific Buprenorphine, by Application USD Million (2021-2026)
  • Table 157. Asia Pacific Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 158. Asia Pacific Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 159. Asia Pacific Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 160. China Buprenorphine, by Application USD Million (2021-2026)
  • Table 161. China Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 162. China Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 163. China Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 164. Japan Buprenorphine, by Application USD Million (2021-2026)
  • Table 165. Japan Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 166. Japan Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 167. Japan Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 168. India Buprenorphine, by Application USD Million (2021-2026)
  • Table 169. India Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 170. India Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 171. India Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 172. South Korea Buprenorphine, by Application USD Million (2021-2026)
  • Table 173. South Korea Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 174. South Korea Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 175. South Korea Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 176. Australia Buprenorphine, by Application USD Million (2021-2026)
  • Table 177. Australia Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 178. Australia Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 179. Australia Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 180. Rest of Asia-Pacific Buprenorphine, by Application USD Million (2021-2026)
  • Table 181. Rest of Asia-Pacific Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 182. Rest of Asia-Pacific Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 183. Rest of Asia-Pacific Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 184. Europe Buprenorphine, by Country USD Million (2021-2026)
  • Table 185. Europe Buprenorphine, by Application USD Million (2021-2026)
  • Table 186. Europe Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 187. Europe Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 188. Europe Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 189. Germany Buprenorphine, by Application USD Million (2021-2026)
  • Table 190. Germany Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 191. Germany Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 192. Germany Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 193. France Buprenorphine, by Application USD Million (2021-2026)
  • Table 194. France Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 195. France Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 196. France Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 197. Italy Buprenorphine, by Application USD Million (2021-2026)
  • Table 198. Italy Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 199. Italy Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 200. Italy Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 201. United Kingdom Buprenorphine, by Application USD Million (2021-2026)
  • Table 202. United Kingdom Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 203. United Kingdom Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 204. United Kingdom Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 205. Netherlands Buprenorphine, by Application USD Million (2021-2026)
  • Table 206. Netherlands Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 207. Netherlands Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 208. Netherlands Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 209. Rest of Europe Buprenorphine, by Application USD Million (2021-2026)
  • Table 210. Rest of Europe Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 211. Rest of Europe Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 212. Rest of Europe Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 213. MEA Buprenorphine, by Country USD Million (2021-2026)
  • Table 214. MEA Buprenorphine, by Application USD Million (2021-2026)
  • Table 215. MEA Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 216. MEA Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 217. MEA Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 218. Middle East Buprenorphine, by Application USD Million (2021-2026)
  • Table 219. Middle East Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 220. Middle East Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 221. Middle East Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 222. Africa Buprenorphine, by Application USD Million (2021-2026)
  • Table 223. Africa Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 224. Africa Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 225. Africa Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 226. North America Buprenorphine, by Country USD Million (2021-2026)
  • Table 227. North America Buprenorphine, by Application USD Million (2021-2026)
  • Table 228. North America Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 229. North America Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 230. North America Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 231. United States Buprenorphine, by Application USD Million (2021-2026)
  • Table 232. United States Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 233. United States Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 234. United States Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 235. Canada Buprenorphine, by Application USD Million (2021-2026)
  • Table 236. Canada Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 237. Canada Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 238. Canada Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 239. Mexico Buprenorphine, by Application USD Million (2021-2026)
  • Table 240. Mexico Buprenorphine, by Side Effect USD Million (2021-2026)
  • Table 241. Mexico Buprenorphine, by Distribution Channel USD Million (2021-2026)
  • Table 242. Mexico Buprenorphine, by Dosages USD Million (2021-2026)
  • Table 243. Research Programs/Design for This Report
  • Table 244. Key Data Information from Secondary Sources
  • Table 245. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Buprenorphine: by Application USD Million (2015-2020)
  • Figure 5. Global Buprenorphine: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Buprenorphine: by Dosages USD Million (2015-2020)
  • Figure 7. South America Buprenorphine Share (%), by Country
  • Figure 8. Asia Pacific Buprenorphine Share (%), by Country
  • Figure 9. Europe Buprenorphine Share (%), by Country
  • Figure 10. MEA Buprenorphine Share (%), by Country
  • Figure 11. North America Buprenorphine Share (%), by Country
  • Figure 12. Global Buprenorphine share by Players 2020 (%)
  • Figure 13. Global Buprenorphine share by Players (Top 3) 2020(%)
  • Figure 14. Global Buprenorphine share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Siegfried Pharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Siegfried Pharma AG (Switzerland) Revenue: by Geography 2020
  • Figure 18. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 19. Sanofi (France) Revenue: by Geography 2020
  • Figure 20. Johnson Matthey (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Johnson Matthey (United Kingdom) Revenue: by Geography 2020
  • Figure 22. Mallinckrodt (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Mallinckrodt (United Kingdom) Revenue: by Geography 2020
  • Figure 24. Noramco (United States) Revenue, Net Income and Gross profit
  • Figure 25. Noramco (United States) Revenue: by Geography 2020
  • Figure 26. Unichem Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 27. Unichem Laboratories (India) Revenue: by Geography 2020
  • Figure 28. Arevipharma GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Arevipharma GmbH (Germany) Revenue: by Geography 2020
  • Figure 30. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 31. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2020
  • Figure 32. Rusan Pharma (India) Revenue, Net Income and Gross profit
  • Figure 33. Rusan Pharma (India) Revenue: by Geography 2020
  • Figure 34. Micro Orgo Chem (India) Revenue, Net Income and Gross profit
  • Figure 35. Micro Orgo Chem (India) Revenue: by Geography 2020
  • Figure 36. Global Buprenorphine: by Application USD Million (2021-2026)
  • Figure 37. Global Buprenorphine: by Distribution Channel USD Million (2021-2026)
  • Figure 38. Global Buprenorphine: by Dosages USD Million (2021-2026)
  • Figure 39. South America Buprenorphine Share (%), by Country
  • Figure 40. Asia Pacific Buprenorphine Share (%), by Country
  • Figure 41. Europe Buprenorphine Share (%), by Country
  • Figure 42. MEA Buprenorphine Share (%), by Country
  • Figure 43. North America Buprenorphine Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Siegfried Pharma AG (Switzerland)
  • Sanofi (France)
  • Johnson Matthey (United Kingdom)
  • Mallinckrodt (United Kingdom)
  • Noramco (United States)
  • Unichem Laboratories (India)
  • Arevipharma GmbH (Germany)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Rusan Pharma (India)
  • Micro Orgo Chem (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation